SynthoPlate
Uncontrolled Bleeding (Trauma, Surgery, Thrombocytopenia)
Pre-clinicalActive
Key Facts
Indication
Uncontrolled Bleeding (Trauma, Surgery, Thrombocytopenia)
Phase
Pre-clinical
Status
Active
Company
About Haima Therapeutics
Haima Therapeutics is pioneering a synthetic platelet technology platform to address critical unmet needs in hemostasis. The company's lead product, SynthoPlate, is an IV-injectable hemostatic agent designed for use in trauma, surgery, and thrombocytopenia, aiming to overcome the severe limitations of donor-derived platelets. By utilizing a fully synthetic, tunable nanoparticle system, Haima seeks to create stable, portable, and universally compatible therapies that can be deployed from the battlefield to the clinic. The platform's versatility also suggests potential applications beyond bleeding, including thrombosis, inflammation, and cancer.
View full company profile